Skip to main content

CITADEL ADVISORS LLC

Position in INBX — Inhibrx Biosciences, Inc.

CIK 1423053 MIAMI, FL

Position in INBX

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$2,229,144
+$104,044 QoQ
Shares Held
33,157
+23.3% QoQ
Ownership
0.226%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Sep 2024
6 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in INBX Over Time

Shares Held

Position Value (USD)

Derivatives in INBX

reported options exposure · as of Mar 31, 2026
CallValue
$2,312,712
CallShares
34,400
PutValue
$242,028
PutShares
3,600

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $5,780,537,601 across 374 Biotechnology names. INBX ranks #190 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in INBX

Export CSV
13 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $2,312,712 34,400
2026-03-31 $242,028 3,600
2026-03-31 $2,229,144 33,157
2025-12-31 $2,125,100 26,900
2025-12-31 $3,460,200 43,800
2025-12-31 $10,854,600 137,400
2025-09-30 $1,926,293 57,194
2025-03-31 $496,645 35,500
2025-03-31 $5,596 400
2024-12-31 $21,560 1,400
2024-12-31 $534,765 34,725
2024-09-30 $90,828 5,800
2024-09-30 $760,684 48,575